-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 6, Hengrui Medicine issued an announcement stating that the main research endpoint of the Phase III clinical trial of SHR8554 injection (SHR8554-301) developed by the company and its subsidiaries Shanghai Hengrui Pharmaceutical Co.
The SHR8554-301 study is a phase III clinical study evaluating the effectiveness and safety of SHR8554 injection for post-abdominal analgesia
A total of 528 subjects were enrolled in this study.